KURA Stock Risk & Deep Value Analysis
Kura Oncology Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on KURA
We analyzed Kura Oncology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KURA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when KURA moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈KURA Performance Overview3yr weekly
Unlock KURA Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
KURA Quality Rating
KURA Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Kura Oncology Inc (KURA)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$683.67M
KURA Deep Value Analysis
KURA Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
KURA Red Flags & Warning Signs
- ⚠
Disappointing KOMZIFTI sales figures in upcoming earnings reports
- ⚠
Negative or inconclusive data from H2 2026 ziftomenib combo trial
- ⚠
Competitor entry or unexpected clinical trial success in the NPM1-mutant AML space
- ⚠
Further delays in KOMET-017 Phase 3 trial or regulatory approval timelines
Unlock KURA Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
KURA Financial Health Metrics
Market Cap
$683.67M
P/E Ratio
-2.73
Profit Margin
-41.30%
Debt-to-Equity
0.12
Dividend Yield
0.00%
Beta (Volatility)
0.25
Earnings Per Share
$-3.18
KURA Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property around ziftomenib as a first-in-class menin inhibitor for NPM1-mutant AML. Switching costs can develop as patients are successfully treated. The durability relies on successful pipeline development and establishing ziftomenib as the standard of care before competitors can bring similar drugs to market.
KURA Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
KURA Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings on Apr 30, 2026 (focus on KOMZIFTI sales ramp)
- •H2 2026: Ziftomenib/gilteritinib combo data in relapsed/refractory NPM1/FLT3-mutated AML
Medium-Term (6-18 months)
- •Continued commercialization ramp-up of KOMZIFTI in relapsed/refractory NPM1-mutant AML (through 2027)
- •Potential Kyowa Kirin milestones up to $180M by early 2027
- •Expansion of KOMZIFTI into additional indications or geographies via partnerships
Long-Term (18+ months)
- •KOMET-017 Phase 3 topline data (2028) for first-line NPM1-mutant AML (potential approval 2029)
- •Establishment of ziftomenib as the standard of care in NPM1-mutant AML
- •Pipeline expansion beyond ziftomenib
Catalysts & Growth Drivers
Sign up free to see growth catalysts
KURA Bull Case: What Could Go Right
- ✓
Acceleration in KOMZIFTI revenue growth in Q1 2026 and subsequent quarters
- ✓
Positive clinical data readouts for ziftomenib combination therapies
- ✓
Analyst upgrades and increased institutional ownership
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Kura Oncology Inc (KURA)?
As of April 10, 2026, Kura Oncology Inc has a DVR Score of 5.5 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Kura Oncology Inc?
Kura Oncology Inc's market capitalization is approximately $683.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Kura Oncology Inc use?
KURA is the ticker symbol for Kura Oncology Inc. The company trades on the NMS.
What is the risk level for KURA stock?
Our analysis rates Kura Oncology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of KURA?
Kura Oncology Inc currently has a price-to-earnings (P/E) ratio of -2.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Kura Oncology Inc's revenue growing?
Kura Oncology Inc has reported revenue growth of 25.2%. The company is showing strong top-line momentum.
Is KURA stock profitable?
Kura Oncology Inc has a profit margin of -41.3%. The company is currently unprofitable.
How often is the KURA DVR analysis updated?
Our AI-powered analysis of Kura Oncology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 10, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.